Effect of Foveal Cyst Size on the Visual Prognosis in Diabetic Macular Edema
Durgül AÇAN1, Mahmut KAYA2, Arif Taylan ÖZTÜRK3, Ziya AYHAN2, Süleyman KAYNAK4, Nilüfer KOÇAK4
1M.D. Bozyaka Training and Research Hospital Eye Clinic, Izmir/TURKEY 2M.D. Dokuz Eylul University Faculty of Medicine Department of Ophthslmology, Izmir/TURKEY 3M.D. Asistant Professor, Dokuz Eylul University Faculty of Medicine Department of Ophthslmology, Izmir/TURKEY 4M.D. Professor, Dokuz Eylul University Faculty of Medicine Department of Ophthslmology, Izmir/TURKEY
Purpose: To evaluate the effect of intraretinal foveal cyst size prior to the treatment on the response of treatment and visual prognosis in patients treated
with intravitreal ranibizumab for diabetic macular edema (DME).
Materials and Methods: One hundred seventy-five eyes of 115 patients diagnosed as DME in our retina clinic between April 2009-June 2014 were
included. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) of the patients were recorded before and after the treatment of
intravitreal ranibizumab. The patients were classified into 3 groups according to the foveal cyst sizes on the baseline spectral-domain optical coherence
tomography (SD-OCT) findings (Group 1; ≤300 mm, Group 2; 300-600 mm, Group 3; ≥600 mm).
Results: The mean age of the patients was 60.24±8.49 (36-81) years and the mean of follow-up time was 22.64±12.03 (4-50) months. The number of
enjections administered to the groups was similar (p>0.05). A significant improvement in visual acuity was provided in all 3 groups treated with ranibizumab.
There wasn’t any significant difference in BCVA between the groups in both baseline and final examinations. A significant reduction in CMT
with ranibizumab treatment was found in all 3 groups. There was significant difference between the groups before the treatment, but there wasn’t after
ranibizumab treatment. There was no correlation between BCVA and the cyst size (r=0.138, p=0.196) and CMT (r=0.102, p=0.115).
Conclusion: It was found that the cyst size is not the only prognostic factor in the response to ranibizumab treatment with respect to visual acuity and
macular thickness in DME.